Form 4: BioCryst Pharmaceuticals Director Steve Aselage Acquires Shares
SEC Form 4 Filing
Director Steve Aselage purchased 2,500 shares of BioCryst Pharmaceuticals at $6.40 per share on May 24, 2024.
Summary
- On May 24, 2024, Steve Aselage, a director of BioCryst Pharmaceuticals, acquired 2,500 shares of common stock at a price of $6.40 per share.
- The transaction was executed through a purchase (Transaction Code 'P').
- Following the transaction, Mr. Aselage directly owns 63,339 shares and indirectly owns 2,500 shares through a trust.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. A director purchasing shares suggests confidence, but the purchase is relatively small and may not be highly significant.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.
Stakeholder Impact
- The stock purchase by a director could positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/24/2024 | Date of stock purchase transaction |
| 05/29/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.